Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

'Speed scanner' can test thousands of plant gene switches at once

Agriculture, from the outset, has been made possible by humans tweaking the genes of plants to make them grow faster, produce ...

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosineCHICAGO, Dec. 24, 2025 (GLOBE ...
24/7 Wall St. on MSN

The biggest IPO of the year prompts huge insider buy

As the year winds down, many investors are positioning themselves for 2026 and beyond. Some insiders made big insider ...

CSUCI contributes millions in statewide economic activity, tax revenue

Cal State Channel Islands (CSUCI) is a powerful driver of opportunity and economic vitality for Ventura County, the Central ...

2026 Market Outlook: S&P 500 Looks Expensive, But Biotech Could Outperform Under The Hood

Discover 2026 stock market outlook: earnings-driven gains, potential sector rotation, biotech opportunities, and Fed policy ...
TMCnet

MAIA Biotechnology Announces $1.51 Million Private Placement

The gross proceeds from the offering are expected to be approximately $1.51 million, prior to offering expenses payable by the Company. The Company intends to use the net proceeds from the offering ...
Yardbarker on MSN

What is 'Fallout' season 2 brain-computer interface implant chip and why is it important?

Fallout season two is kicking off with a bang… Literally, if you’re one of a few unlucky people who cross paths with Mr. House or Hank MacLean. But what is that’s making people’s heads go bang?

MAIA Biotechnology, Inc.: MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ...

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that it has entered into definitive agreements in a ...